AlgoTx

AlgoTx is a clinical stage biotechnology company focused on developing targeted therapeutics for peripheral neuropathic pain. The company's lead product, ATX01, is a non-opioid, locally acting treatment designed for Chemotherapy-Induced Peripheral Neuropathy. It has secured Fast-Track designation from the FDA. Currently, the company is conducting the ACT study, a Phase II trial involving over 270 patients, with results expected in early 2025 and plans for an expedited Phase 3 trial. AlgoTx boasts seasoned leadership, a strong international board, and has raised a total of EUR 35 million, including a EUR 20 million Series B round in 2023. Notable investors in the company include Relyens Innovation Santé / Turenne Capital, UI Investissement, Bpifrance through its Innobio 2 fund, Omnes Capital, and angel investors. In addition, in 2023, the company was honored with France Biotech’s ESG HealthTech Trophy for its early commitment to ESG initiatives. Overall, AlgoTx demonstrates promise in addressing a significant medical need with its innovative approach and strong financial backing, making it an intriguing prospect for venture capital investment. For more details, visit the company's website.